Belgian drug major UCB (Euronext: UCB) outpaced revenue expectations for 2022, taking in 5.52 billion euros ($5.9 billion), well ahead of the FT consensus forecast of 5.34 billion euros.
The revenue result represents a 4% year-on-year drop, with net sales coming in at 5.14 billion euros and the earnings per share (EPS) figure reaching 4.37 euros.
UCB is suffering from the loss of exclusivity for E Keppra (levetiracetam) in Japan and Vimpat (lacosamide) in the USA and Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze